Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises
W. Li, Y. Wang, X. Liu, S. Wu, M. Wang, S. G. Turowski, J. A. Spernyak, A. Tracz, A. M. Abdelaal, K. Sudarshan, I. Puzanov, G. Chatta, A. L. Kasinski, D. G. Tang
This study evaluates folate-conjugated miR-34a as a potential prostate cancer therapeutic, finding limited efficacy due to low FOLR1 expression in prostate cancer cells.
bioRxiv · Nov 25, 2023 · PreprintCancer Biology